Form 4: Analog Devices CEO Vincent Roche Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4
Analog Devices' Chair and CEO, Vincent Roche, exercised stock options and sold 10,000 shares of common stock at $195.83 per share on March 4, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- On March 4, 2024, Vincent Roche, Chair & CEO of Analog Devices Inc., executed a non-qualified stock option to acquire 10,000 shares of common stock at an exercise price of $83.48.
- Concurrently, Roche sold 10,000 shares of Analog Devices common stock at a price of $195.83 per share.
- These transactions were conducted under a pre-arranged 10b5-1 trading plan adopted on April 6, 2023.
- Following these transactions, Roche directly owns 5,713 shares and indirectly owns 55,000 shares through the Vincent Roche 2023 Grantor Retained Annuity Trust.
- He also directly owns 20,000 non-qualified stock options.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The document simply reports transactions by an executive under a pre-existing plan. There is no indication of positive or negative implications for the company.
Positives
- The transactions were executed under a pre-arranged 10b5-1 trading plan, which is generally viewed as a transparent and compliant practice.
Future Outlook
There is no future outlook provided in this document.
Industry Context
Executive stock transactions are common and closely monitored in the semiconductor industry. Sales under 10b5-1 plans are generally viewed as less impactful than discretionary sales, as they are pre-planned.
Comparison to Industry Standards
- Executive compensation practices, including stock options and equity grants, are standard across the semiconductor industry.
- Companies like Texas Instruments (TXN), Qualcomm (QCOM), and Nvidia (NVDA) also utilize stock options as part of their executive compensation packages.
- The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies to avoid accusations of insider trading.
- The vesting schedules and exercise prices of stock options are typically benchmarked against industry peers to ensure competitiveness and alignment with shareholder interests.
Stakeholder Impact
- The sale of shares by the CEO could have a minor impact on shareholder sentiment, but the existence of a 10b5-1 plan mitigates concerns about insider trading.
Key Dates
| Date | Description |
|---|---|
| 03/08/2017 | Original grant date of the non-qualified stock option, which vested in equal installments over five years. |
| 03/08/2018 | First vesting date of the non-qualified stock option. |
| 04/06/2023 | Date the Reporting Person adopted the 10b5-1 plan. |
| 08/25/2023 | Date of the Vincent Roche 2023 Grantor Retained Annuity Trust. |
| 03/04/2024 | Date of the stock option exercise and share sale. |
| 03/05/2024 | Date of the signature on the Form 4 filing. |
| 03/08/2027 | Expiration date of the non-qualified stock option. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.